Insider Transaction: Tench Coxe Acquired 225,253 Shares of Mattersight (MATR), Cytori Therapeutics (CYTX) Had 4 Bullish Analysts

June 5, 2017 - By Richard Conner

Among 5 analysts covering Cytori Therapeutics (NASDAQ:CYTX), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Cytori Therapeutics has $1000 highest and $1.50 lowest target. $5.31’s average target is 415.53% above currents $1.03 stock price. Cytori Therapeutics had 6 analyst reports since August 8, 2015 according to SRatingsIntel. Maxim Group maintained the stock with “Buy” rating in Wednesday, May 31 report. The firm has “Hold” rating given on Friday, September 4 by Zacks. The firm has “Buy” rating given on Monday, August 10 by TH Capital. The rating was maintained by Maxim Group with “Buy” on Saturday, August 8. See Cytori Therapeutics Inc (NASDAQ:CYTX) latest ratings:

31/05/2017 Broker: Maxim Group Rating: Buy New Target: $10.0000 Maintain
16/12/2016 Broker: B. Riley & Co Rating: Buy New Target: $5.75 Initiates Coverage On

As disclosed in a legally required document filed with the Washington-based SEC on 01/06/2017, Tench Coxe, director of Mattersight Corp and an insider, picked up 225,253 shares of the firm for exactly $822,016 US Dollars calculated with average price per share of $3.6. Mr. Tench now holds 3.05 million shares, accounting for 10%+ of Mattersight Corp’s market capitalization.

Cytori Therapeutics, Inc. is a biotechnology firm engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The company has market cap of $33.78 million. The Firm develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It currently has negative earnings. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation.

The stock increased 0.98% or $0.01 on June 2, reaching $1.03. About shares traded. Cytori Therapeutics Inc (NASDAQ:CYTX) has declined 65.60% since June 5, 2016 and is downtrending. It has underperformed by 82.30% the S&P500.

Since February 16, 2017, it had 3 insider purchases, and 2 selling transactions for $607,050 activity. MULLEN DAVID B also bought $51,598 worth of Mattersight Corp (NASDAQ:MATR) on Wednesday, May 17. Shares for $345,000 were bought by COXE TENCH. Danson Christopher Joseph sold 14,640 shares worth $55,818. On Thursday, February 23 the insider Investor Growth Capital – LLC bought $354,561.

The stock decreased 1.89% or $0.05 on June 2, reaching $2.6. About shares traded. Mattersight Corp (NASDAQ:MATR) has declined 29.56% since June 5, 2016 and is downtrending. It has underperformed by 46.26% the S&P500.

Investors sentiment increased to 1.75 in 2016 Q4. Its up 0.90, from 0.85 in 2016Q3. It is positive, as 3 investors sold Mattersight Corp shares while 5 reduced holdings. 4 funds opened positions while 10 raised stakes. 8.69 million shares or 4.83% more from 8.29 million shares in 2016Q3 were reported. Bank Of America Corporation De, a North Carolina-based fund reported 137 shares. Tiaa Cref Mngmt Limited Liability Co holds 31,528 shares or 0% of its portfolio. Stifel Corp reported 0% stake. Blackrock Fund Advisors accumulated 49,262 shares or 0% of the stock. Moreover, Howe Rusling has 0% invested in Mattersight Corp (NASDAQ:MATR) for 400 shares. Geode Mgmt Ltd Llc has invested 0% in Mattersight Corp (NASDAQ:MATR). Vanguard Gp Inc stated it has 0% in Mattersight Corp (NASDAQ:MATR). Ironwood Mgmt Ltd holds 0.33% or 121,887 shares in its portfolio. S Squared Tech Ltd Liability Corp holds 1.88% or 467,927 shares in its portfolio. Blackrock Invest Mgmt reported 3,208 shares. California Employees Retirement Sys owns 35,227 shares for 0% of their portfolio. New York-based Fincl Bank Of New York Mellon has invested 0% in Mattersight Corp (NASDAQ:MATR). Boston Prns owns 0% invested in Mattersight Corp (NASDAQ:MATR) for 715,648 shares. Barclays Plc stated it has 0% of its portfolio in Mattersight Corp (NASDAQ:MATR). Tower Rech Cap Ltd Llc (Trc) holds 1,575 shares or 0% of its portfolio.

Mattersight Corporation offers behavioral analytics and provides personality software products. The company has market cap of $83.38 million. The Firm uses various applications, including predictive behavioral routing, performance management, quality assurance and predictive analytics to analyze and predict customer behavior based on the language exchanged between agents and clients during brand interactions. It currently has negative earnings. The Firm operates through the Behavioral Analytics segment.